Last reviewed · How we verify
Plasma-lyte
Plasma-Lyte is a balanced electrolyte solution that replaces fluid and electrolytes lost through dehydration, hemorrhage, or other medical conditions.
Plasma-Lyte is a balanced electrolyte solution that replaces fluid and electrolytes lost through dehydration, hemorrhage, or other medical conditions. Used for Fluid resuscitation in trauma, burns, and hemorrhage, Perioperative fluid maintenance, Treatment of dehydration and electrolyte imbalances.
At a glance
| Generic name | Plasma-lyte |
|---|---|
| Also known as | Balanced cristalloids, Plasma-Lyte 148, Plasmalyte, PL, ATC: B 05 BB 01 |
| Sponsor | Fundación Santa Fe de Bogota |
| Drug class | Crystalloid intravenous fluid / Electrolyte replacement solution |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Fluid and Electrolyte Management |
| Phase | FDA-approved |
Mechanism of action
Plasma-Lyte is a crystalloid intravenous fluid containing a physiologically balanced mixture of electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate) designed to mimic plasma composition. It is used for fluid resuscitation and maintenance therapy to restore intravascular volume and correct electrolyte imbalances in hospitalized patients.
Approved indications
- Fluid resuscitation in trauma, burns, and hemorrhage
- Perioperative fluid maintenance
- Treatment of dehydration and electrolyte imbalances
Common side effects
- Hyperchloremic acidosis
- Fluid overload / pulmonary edema
- Hypokalemia
- Injection site reactions
Key clinical trials
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Precision Resuscitation With Crystalloids in Sepsis (NA)
- Descartes-08 in Autoantibody Myositis (PHASE2)
- Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge (PHASE1)
- Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis (PHASE3)
- Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) (PHASE1, PHASE2)
- Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) (PHASE2)
- CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plasma-lyte CI brief — competitive landscape report
- Plasma-lyte updates RSS · CI watch RSS
- Fundación Santa Fe de Bogota portfolio CI